MIAMI, July 1 /PRNewswire/ — FUISZ today
announced two medical technology advances.
First, FUISZ announced that it has received a notice of issuance
from the United States Patent and Trademark Office for patent
claims that cover a direct connection between prescribing
physicians and blood analysis devices. The invention allows
for the health care provider to set the parameters of allowable
analyte levels for each patient and enables simple notifications
for any variance out of a pre-determined range. Joseph Fuisz, managing member of FUISZ
stated, “These patent claims represents a quantum leap in the use
of portable blood analyzers to provide a higher level of care for
patients while reducing burdens on health care providers. We are in
discussions with the blood analyzer industry for the licensing of
this technology.”
FUISZ also announced that it has filed a new patent in the field
of solid oral Bioactive dosage forms. This novel system works to
enhance or retard drug absorption. It is particularly well
suited to buccal, sublinqual and other forms of mucosal delivery
including nano particles. Joseph Fuisz commented, “This
innovation can be readily adapted for use with existing products to
improve control of drug absorption. It will be particularly
well received in the opiate market where controlling relative
absorption of opiates and agonists is so critical. This
technology draws upon our deep knowledge of quick dissolve dosage
forms and applies that knowledge in a broad manner to all solid
dosage forms.”
FUISZ is a family owned company. Fuisz principals Richard Fuisz, M.D. and Joseph Fuisz, Esq. are named inventors on
or owners of hundreds of patents and patent appli
‘/>”/>
SOURCE
